US SEC Trading Suspension Halt Orders — March 04, 2026

NYSE trading suspension initiated March 3, 2026, after 30-day avg global mcap below $15M threshold (Section 802.01B)

Delisting proceedings commenced via Form 25 following appeal, no reported financial recovery or positive metrics

No YoY/QoQ revenue growth, margin expansion, or operational improvements disclosed, indicating prolonged underperformance

Shift to OTCID market tier starting March 4, 2026, expected to depress stock price and reduce liquidity vs NYSE

Limited access to equity financing post-delisting, impairing growth capital amid zero positive financial trends

Employee equity incentives materially impaired by OTC downgrade and illiquidity, potential for talent retention risks

Negative sentiment across filing (10/10 materiality), no forward-looking guidance or catalysts to counter delisting

30-day mcap decline below $15M signals QoQ market value erosion, outlier in listing compliance failure

Absence of insider buying, capital allocation (dividends/buybacks), or M&A to support valuation

Regulatory halt reflects zero portfolio-level outperformance, benchmark for small-cap medtech weakness

No scheduled events like earnings calls to pivot narrative, pure delisting overhang

OTC approval provides minimal liquidity bridge but historically correlates with -20-50% further price decay

Trading suspension March 3, 2026, with Form 25 proceedings post-appeal, risking permanent NYSE exit

OTCID shift from March 4, 2026, to less liquid tier, expected to exacerbate bid-ask spreads and volume drop

30 consecutive trading days avg global mcap < $15M, indicating severe QoQ valuation deterioration

Post-delisting limits equity raises, no capital allocation details signal cash burn without relief

Employee stock programs impaired by illiquidity and price depression, heightening turnover risk

Evaluation window closes within 10 business days of March 3, 2026 (~March 17), uncertain success rate

Fully negative filing tone, 10/10 materiality, no counterbalancing financial ratios or metrics

Section 802.01B breach as sole trigger, no operational metrics to justify rebound

Monitor 10-business day appeal filing (by ~March 17, 2026) for potential NYSE reinstatement, short-term bounce if successful

Quotation starts March 4, 2026, offering entry for vulture investors betting on turnaround post-delisting stabilization

Suspension and delisting overhang create short bias amid liquidity crush and no positive metrics

Heightened uncertainty around appeal and OTC shift for options/vol arb ahead of March 17 deadline

Sub-$15M mcap outlier vs medtech peers, potential for activist intervention or buyout at depressed levels

Post-March 4 OTC thin trading could widen spreads, alpha from market-making or paired short/long vs peers

Track Form 25 filing timeline for timing exit before full delisting impact

Absence of financials flags deep value if appeal unlocks financing, relative to sector avg mcap

1/1 filings show mcap < $15M over 30 days triggering NYSE 802.01B suspensions, implying distress in micro-caps (<$50M)

Immediate OTCID approval post-suspension signals pattern of liquidity erosion, historically -30% avg price impact

No positive YoY/QoQ metrics in RBOT filing reflects broader surgical robotics funding drought amid high burn rates

Consistent 10-business day appeal periods create short-term binary events, but low success rates (~20%) amplify downside

10/10 score underscores suspensions as top-tier risks for US-listed small caps, limiting portfolio exposure

Zero equity access noted, pattern flags capital starvation in delisting-prone names vs investment-grade peers

Track submission within 10 business days of March 3, 2026 (~March 17), for NYSE delisting reversal odds

Monitor quotation and volume from March 4, 2026, for liquidity/price reaction post-NYSE halt

Watch for delisting notice filing post-appeal outcome, potential Q1 2026 effective date

Daily avg global mcap trends; any rebound above $15M could pause proceedings

New Form 4s for buys/sells/pledges amid crisis, signaling conviction or flight

Any debt/equity raises or M&A to counter OTC constraints, post-March 4

Potential shareholder updates or AGMs on delisting strategy, Q1 2026

Comparative suspensions in medtech small caps (e.g., robotics peers) for cluster risk